Dr. Eklund is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8915 W Golf Rd
Fl 3
Niles, IL 60714Phone+1 847-827-9060Fax+1 847-827-7196
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2002 - 2005
- McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1998 - 2002
- University of Illinois College of MedicineClass of 1998
- University of Illinois at Urbana-ChampaignBS, Biology, Summa Cum Laude, 1990 - 1994
Certifications & Licensure
- IL State Medical License 2000 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer Start of enrollment: 2020 Feb 06
Publications & Presentations
PubMed
- 1 citationsReport of Cholangiocarcinoma With Transheterozygous BRCA1 and BRCA2 Co-mutation.Nicholas Prabhakar, Harrah Chiang, Edward Nabrinsky, John Eklund
Cureus. 2024-05-01 - 14 citationsA Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)Elizabeth A. Atchison, John W. Eklund, Brenda Martone, Lili Wang, Adi Gidron
Journal of Immunotherapy. 2010-09-01 - 16 citationsPhase II study of denileukin diftitox for previously treated indolent non-Hodgkin lymphoma: final results of E1497.Timothy M. Kuzel, Shuli Li, John W. Eklund, Francine M. Foss, Randy D. Gascoyne
Leukemia & Lymphoma. 2007-10-13
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: